Drug
Qm1114 DP
Qm1114 DP: highest development phase Phase 3, developed by Galderma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Galderma
Trials
| Drug | Phase | Indication |
|---|---|---|
| QM1114-DP NCT05148000 | Phase 3 | Glabellar Frown Lines |
Latest
No recent events.
Follow Qm1114 DP on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.